The future of immunotherapy in multiple myeloma
Hearn Cho et al.
The potential of biosimilar rituximab: reducing budgets and increasing access to treatment
Drug resistance in multiple myeloma: addressing the issue
Brian Van Ness
Exciting insights into the role of ROR1 in CLL
Multiple myeloma: consensuses and controversies
Faith Davies et al.